



NDA 022107/S-022

**SUPPLEMENT APPROVAL**

Novartis Pharmaceuticals Corporation  
Attention: Leigh Strachan  
Global Program Regulatory Affairs, Drug Regulatory Affairs  
One Health Plaza  
East Hanover, NJ 07936

Dear Ms. Strachan:

Please refer to your Supplemental New Drug Application (sNDA) dated and received August 1, 2012, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Tekturna HCT (aliskiren/hydrochlorothiazide) 150/12.5 mg, 150/250 mg, 300/12.5 mg, and 300/25 mg Tablets.

This "Prior Approval" supplemental new drug application provides for labeling revised as follows (additions are marked as underlined text and deletions are marked as ~~strickethrough text~~):

1. In **HIGHLIGHTS/RECENT MAJOR CHANGES**, the following text was added:

Boxed Warning: Fetal Toxicity	02/2012
Contraindications: Concomitant use with ARBs or ACEIs in diabetes (4)	03/2012
Warnings and Precautions ( <u>5.1</u> )	02/2012
Warnings and Precautions ( <u>5.2</u> , <u>5.4</u> , <u>5.5</u> , <u>5.9</u> )	03/2012
<u>Warnings and Precautions (5.3)</u>	<u>xx/2012</u>

2. In **HIGHLIGHTS/WARNINGS AND PRECAUTIONS**, the following text was added to the second bullet:

- Anaphylactic Reactions and Head and Neck Angioedema: Discontinue Tekturna HCT and monitor until signs and symptoms resolve. (5.3)

3. Under **CONTRAINDICATIONS**, the cross reference was updated:

Do not use aliskiren with ARBs or ACEIs in patients with diabetes [*see Warnings and Precautions (5.2), Clinical ~~Studies-Trials~~(14.4)*].

4. In **WARNINGS AND PRECAUTIONS** the following text was added:

**5.3 Anaphylactic Reactions and Head and Neck Angioedema**

Aliskiren

Hypersensitivity reactions such as anaphylactic reactions and angioedema of the face, extremities, lips, tongue, glottis and/or larynx have been reported in patients treated with

Tekturna and has necessitated hospitalization and intubation. This may occur at any time during treatment and has occurred in patients with and without a history of angioedema with ACE inhibitors or angiotensin receptor antagonists. Anaphylactic reactions have been reported from post-marketing experience with unknown frequency. If angioedema involves the throat, tongue, glottis or larynx, or if the patient has a history of upper respiratory surgery, airway obstruction may occur and be fatal. Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. Prompt administration of subcutaneous epinephrine solution 1:1000 (0.3 to 0.5 ml) and measures to ensure a patent airway may be necessary.

Discontinue Tekturna HCT immediately in patients who develop anaphylactic reactions or angioedema, and do not readminister.

5. In **ADVERSE REACTIONS/Post-Marketing Experience**, the following text was added:

*Hypersensitivity: anaphylactic reactions and angioedema requiring airway management and hospitalization*

6. In **PATIENT COUNSELING INFORMATION**, the following text was added:

*Anaphylactic Reactions and Angioedema*

Patients should be advised and told to report immediately any signs or symptoms suggesting a severe allergic reaction (difficulty breathing or swallowing, tightness of the chest, hives, general rash, swelling, itching, dizziness, vomiting, or abdominal pain) or angioedema (swelling of face, extremities, eyes, lips, tongue, difficulty in swallowing or breathing) and to take no more drug until they have consulted with the prescribing physician. Angioedema, including laryngeal edema, may occur at any time during treatment with Tekturna HCT.

7. In **FDA-Approved Patient labeling**, under **What are the possible side effects of Tekturna HCT?,,** the following section was added:

- **Severe Allergic Reactions and Angioedema.** Aliskiren, one of the medicines in Tekturna HCT, can cause difficulty breathing or swallowing, tightness of the chest, hives, general rash, swelling, itching, dizziness, vomiting, or abdominal pain (signs of a severe allergic reaction). Aliskiren can also cause swelling of the face, lips, tongue, throat, arms and legs, or the whole body (signs of angioedema). Get medical help right away and tell your doctor if you get any one or more of these symptoms. Angioedema can happen at any time while you are taking Tekturna HCT.

8. Throughout the label there were editorial revisions noted (i.e. In **CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS**, and **ADVERSE REACTIONS**, the cross references were updated; in **DRUG INTERACTIONS**, NSAIDS was revised to read NSAIDs)

9. The revision date and version number were updated.

There are no other changes from the last approved package insert.

We have completed our review of this supplemental application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

### **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories. Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

### **PROMOTIONAL MATERIALS**

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety

information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN  
Regulatory Project Manager for Safety  
(301) 796-3975

Sincerely,

*{See appended electronic signature page}*

Mary Ross Southworth, Pharm.D.  
Deputy Director for Safety  
Division of Cardiovascular and Renal Products  
Office of Drug Evaluation 1  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MARY R SOUTHWORTH  
09/28/2012